Tumor Testing May Be Increasingly Useful in Ovarian Cancer

May 8, 2023 3:00 pm

Testing tumors with next-generation sequencing in patients with ovarian cancer can provide teams insight into targetable mutations that may affect treatment decisions, although this approach is not the current standard of care for all patients, an expert said.

Among 1,092 patients with ovarian cancer, 27.5% underwent next-generation sequencing; 96.1% had one or more genetic alteration; 25.9% had an alteration that aligned with targeted treatment

In an

Read more

Penn Study Illuminates Why Cancers Caused by BRCA Mutations Recur

November 10, 2022 11:36 am

Findings uncover possible drivers of recurrent breast and ovarian cancers among women carrying high-risk genetic mutations, pointing to methods to more effectively treat disease

PHILADELPHIA — Researchers at the University of Pennsylvania’s Basser Center for BRCA at the Abramson Cancer … Read more

Study could help recommend the best treatment for women with early-stage mucinous ovarian cancer

October 12, 2022 1:23 pm

by Emily Henderson, B.Sc.

A global study into mucinous ovarian cancer could help oncologists recommend the best treatment for women who are diagnosed early with the condition.

By looking down a microscope for two different ‘patterns of invasion’ – the … Read more

FDA Approves Tafinlar Plus Mekinist for Patients With BRAF V600-Mutant Solid Cancers

June 23, 2022 10:56 am

by Brielle Benyon

Tafinlar plus Mekinist is now approved by the Food and Drug Administration to treat adults and children over the age of 6 who have BRAF V600-mutant advanced solid cancers.

The Food and Drug Administration (FDA) approved Tafinlar

Read more

Next-Generation AstraZeneca PARP1 Inhibitor Shows Activity in Multiple Cancers at Variety of Doses

April 12, 2022 1:12 pm

by Alison Kanski

NEW YORK – An investigational AstraZeneca drug that showed activity at a range of doses across differently mutated cancers with limited toxicity exemplifies the versatility of next-generation PARP1 inhibitors, according to researchers at the American Society for … Read more

Elimusertib Shows Promise for Solid Tumors With ATM Loss and DDR Gene Defects

April 10, 2022 2:29 pm

by Ariana Pelosci

Data regarding different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects display early efficacy of the therapy.

Patients with advanced solid tumors who have ATM gene alterations

Read more

MAPK mutations linked to longer survival in ovarian cancer subset

March 24, 2022 10:43 am

by Jennifer Southall

 

Women with mitogen-activated protein kinase-mutated low-grade serous ovarian/peritoneal carcinoma experienced significantly longer PFS and OS compared with women without these mutations, according to study results.

The findings, presented during the Society of Gynecologic Oncology 2022 Annual … Read more

Virtual biopsies may give more accurate results than traditional method thanks to revolutionary technique

July 11, 2021 3:17 pm

CAMBRIDGE, England — Virtual biopsies could replace invasive tissue procedures and give more accurate results thanks to a revolutionary new method developed using computer scans. The new advanced computing technique uses routine medical scans to enable doctors to take fewer, … Read more

How Biomarker Testing May Help Women Battling Ovarian Cancer

February 18, 2021 6:00 pm

Receiving a cancer diagnosis can be overwhelming. But the more you know about your specific situation, the better.

By

Every year, more than 21,000 women in the United States are diagnosed with ovarian cancer. In about half of

Read more

‘Virtual Biopsies’ Could Replace Tissue Biopsies in Future Thanks to Technique Developed by Cambridge Scientists

January 6, 2021 5:00 am

A new advanced computing technique using routine medical scans to enable doctors to take fewer, more accurate tumour biopsies, has been developed by cancer researchers at the University of Cambridge. This is an important step towards precision tissue sampling for

Read more

Large Genomics Study Points the Way to Future Cancer Clinical Trials

October 14, 2020 11:00 am

By Angus Liu

Many oncology researchers and practitioners scrutinize genetic alterations in cancer, but they either focus on one particular tumor type or one mutation that occurs across tumors. A large-scale study focusing on precision medicine in cancer is now … Read more

Tumor Gene Test Could Help to Predict Ovarian Cancer Prognosis

August 17, 2020 6:00 pm

A global team of medical researchers led by UNSW have developed a test that could help to predict survival for women diagnosed with ovarian cancer, and pave the way towards personalised treatment.

A tumour test could help to identify ovarian … Read more

A White Paper on the Need for Consistent Terms for Testing in Precision Medicine

July 7, 2020 7:00 am

For years, The Clearity Foundation has emphasized the importance of tumor profiles/blueprints for informing decisions about treatment for ovarian cancer. Yet, genetic and tumor biomarker testing are not universally performed despite evidence that positive results in these tests could suggest … Read more

New Research Shows Which Ovarian Cancer Patients Won’t Benefit From Immune-PARP Combo

March 19, 2020 10:10 am

BOSTON – In patients with advanced ovarian cancer, a combination of drugs known as immune checkpoint inhibitors and PARP inhibitors can produce powerful remissions, clinical trials have shown, but up until now investigators haven’t been able to predict which patients … Read more

Genetically Definable Subgroups of Cancers Sensitive to Treatment

October 24, 2019 5:00 pm

Precision oncology aims to use genetic features of a patient’s tumor to tailor anti-cancer therapy. DNA mutations in a drug target have provided a number of therapeutic opportunities; however, there are many cancer types that do not have obvious targetable … Read more

‘This terrible disease’: Ovarian cancer is deadly, but new tests, treatments start to emerge

May 18, 2019 5:00 pm

By Sarah Elizabeth Richards

Photo: Liz Laats with husband Andy Laats and their three children. She died three years ago of ovarian cancer. The San Diego resident had suffered through 88 rounds of chemotherapy during 10 treatment regimens over six Read more

Impact of Somatic Molecular Profiling on Clinical Trial Outcomes in Rare Epithelial Gynecologic Cancer Patients

April 25, 2019 6:00 pm

Given that the limited number of patients and differences in biologic behavior pose challenges in conducting clinical trials in rare malignancies, researchers determined whether using genomic profiling for rare gynecologic malignancies is feasible and have clinical utility. They analyzed somatic

Read more

Clearity’s Scientific Director, Dr. Deb Zajchowski, Presents Poster at SGO: Genomic Mutation Profiles of Paired Ovarian Cancers Across Time

March 16, 2019 9:00 am

Clearity’s Scientific Director, Dr. Deb Zajchowski, presented a poster at the SGO’s 50th Annual Meeting on Women’s Cancers entitled: Genomic Mutation Profiles of Paired Ovarian Cancers Across Time.

The data presented describes some of the research being done utilizing The … Read more

From Standard to Personalised Care

November 17, 2018 7:00 pm

Woman with ovarian cancer has incredible response to treatment selected based on her tumor molecular profile. This tumor testing is part of the tumor blueprint that Clearity provides.

By Pierre Valette

“It was definitely a ‘holy smokes’ moment,” recounts Justin … Read more

Open Source Tool Predicts Chemo Drugs Best Suited for Individual Patients

November 12, 2018 12:09 am

Researchers at Georgia Institute of Technology (Georgia Tech) have developed a new open-source decision support tool designed to help clinicians chose the chemotherapy drug best suited for individual patients.

The open-source support vector machine (SVM)-based algorithm predicted the chemotherapy drug … Read more